HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Iontcho R Vlahov Selected Research

EC145

12/2018Pre-clinical evaluation of EC1456, a folate-tubulysin anti-cancer therapeutic.
3/2014Folate-vinca alkaloid conjugates for cancer therapy: a structure-activity relationship.
2/2011Reducing undesirable hepatic clearance of a tumor-targeted vinca alkaloid via novel saccharopeptidic modifications.
9/2009In vivo structural activity and optimization studies of folate-tubulysin conjugates.
10/2007Comparative preclinical activity of the folate-targeted Vinca alkaloid conjugates EC140 and EC145.
5/2007Preclinical evaluation of EC145, a folate-vinca alkaloid conjugate.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Iontcho R Vlahov Research Topics

Disease

20Neoplasms (Cancer)
01/2020 - 11/2002
5Inflammation (Inflammations)
10/2021 - 02/2011
2Polycystic Kidney Diseases (Polycystic Kidney Disease)
01/2019 - 10/2012
2Weight Loss (Weight Reduction)
01/2019 - 05/2007
2Neutropenia
12/2018 - 01/2013
2Carcinoma (Carcinomatosis)
12/2018 - 01/2013
2Experimental Arthritis
07/2015 - 04/2011
2Rheumatoid Arthritis
07/2015 - 04/2011
1Cytokine Release Syndrome
10/2021
1Prostatic Neoplasms (Prostate Cancer)
01/2019
1Uveitis
01/2014
1Encephalomyelitis (Myeloencephalitis)
01/2014
1Neoplasm Metastasis (Metastasis)
01/2013
1Urinary Bladder Neoplasms (Bladder Cancer)
01/2013
1Autosomal Dominant Polycystic Kidney (ADPKD)
10/2012
1Cysts
10/2012
1Arthritis (Polyarthritis)
04/2011
1Constipation
02/2011
1Hypersensitivity (Allergy)
09/2009
1Anaphylaxis (Anaphylactic Shock)
09/2009
1Lymphoma (Lymphomas)
05/2007

Drug/Important Bio-Agent (IBA)

22Folic Acid (Vitamin M)FDA LinkGeneric
01/2019 - 11/2002
10Pharmaceutical PreparationsIBA
01/2020 - 09/2007
6EC145IBA
12/2018 - 05/2007
5Biological ProductsIBA
01/2019 - 07/2005
3tubulysin BIBA
01/2019 - 09/2009
3AlkaloidsIBA
12/2018 - 02/2011
3AminopterinIBA
01/2014 - 02/2011
2EC0531IBA
12/2018 - 06/2017
2EC0305IBA
06/2017 - 09/2009
2EC 0746IBA
01/2014 - 04/2011
1Folate Receptor 2IBA
10/2021
1Chimeric Antigen ReceptorsIBA
10/2021
1InterleukinsIBA
10/2021
1Interleukin-6 (Interleukin 6)IBA
10/2021
1DNA (Deoxyribonucleic Acid)IBA
01/2020
1AntigensIBA
01/2019
1Biomarkers (Surrogate Marker)IBA
01/2019
1Docetaxel (Taxotere)FDA Link
01/2019
1Cisplatin (Platino)FDA LinkGeneric
12/2018
1Paclitaxel (Taxol)FDA LinkGeneric
12/2018
1EC0565IBA
07/2015
1Retinaldehyde (Retinal)IBA
01/2014
1Myelin Basic ProteinIBA
01/2014
1ArrestinIBA
01/2014
1EC0905IBA
01/2013
1Sirolimus (Rapamycin)FDA Link
10/2012
1TOR Serine-Threonine KinasesIBA
10/2012
1MTOR InhibitorsIBA
10/2012
1Pemetrexed (MTA)FDA Link
07/2011
11,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA
07/2011
1Etanercept (Enbrel)FDA Link
04/2011
1Methotrexate (Mexate)FDA LinkGeneric
04/2011
1HydrazinesIBA
02/2011
1EC 0489IBA
02/2011
1HaptensIBA
09/2009
1Fluorescein (Funduscein)FDA LinkGeneric
09/2009
1Fluorescein-5-isothiocyanate (FITC)IBA
09/2009
1EC0225IBA
09/2007
1LigandsIBA
09/2007
1AcidsIBA
05/2007
14,4- difluoro- 4- bora- 3a,4a- diaza- s- indacene (BODIPY)IBA
05/2007
1Mitomycin (Mitomycin-C)FDA LinkGeneric
07/2005

Therapy/Procedure

9Therapeutics
10/2021 - 09/2006
1Drug Therapy (Chemotherapy)
07/2012
1Immunotherapy
09/2009